Are Patients With End-Stage Liver Disease Maximally Vasodilated?: Insights From Rubidium-82 PET Dilatory Perfusion

Coronary artery disease (CAD) is a leading cause of mortality and morbidity among patients with end-stage liver disease (ESLD) undergoing liver transplantation [(1)][1]. The increasing age and burden of traditional CAD risk factors in ESLD patients [(2)][2] warrants accurate risk stratification